Portrait of a patient with systemic lupus erythematosus for the prescription of the type I interferon inhibitor anifrolumab

In recent years the use of monoclonal antibodies that block activity of type I interferon (IFN) or its receptors has become the new approach in the pharmacotherapy of systemic lupus erythematosus (SLE).Objective: to characterize patients with SLE treated with the type I IFN receptor inhibitor anifro...

Full description

Bibliographic Details

Published in:	Современная ревматология
Main Authors:	T. M. Reshetnyak, E. A. Aseeva, A. A. Shumilova, N. Yu. Nikishina, S. Yu. Shkireeva, A. M. Lila
Format:	Article
Language:	Russian
Published:	IMA-PRESS LLC 2023-12-01
Subjects:	systemic lupus erythematosus interferon receptors interferon α anifrolumab
Online Access:	https://mrj.ima-press.net/mrj/article/view/1497